{"nctId":"NCT00573443","briefTitle":"Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS","startDateStruct":{"date":"2007-12"},"conditions":["Pseudobulbar Affect (PBA)"],"count":326,"armGroups":[{"label":"DM 30 mg/Q 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg"]},{"label":"DM 20 mg/ Q 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg","otherNames":["AVP-923","Nuedextaâ„¢","DM 20 mg/ Q 10 mg","DMQ"]},{"name":"dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg","otherNames":["AVP-923","DM 30 mg/ Q 10 mg","DMQ"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* The patient has a diagnosis of Amyotrophic Lateral Sclerosis (according to El Escorial Criteria, WFN, 1998) and the time from diagnosis of ALS is not be longer than 30 months, or the patient has a diagnosis of multiple sclerosis or probable multiple sclerosis (according to McDonald criteria, 2001)\n* The patient has a clinical history and clinical relevant symptoms of Pseudobulbar Affect (PBA)\n* CNS-LS score at baseline is 13 or greater\n\nMain Exclusion Criteria:\n\n* Patients with myasthenia gravis\n* Any personal history of complete heart block, QTc prolongation, or torsades de pointes\n* Any family history of congenital QT interval prolongation syndrome\n* Patients with known sensitivity to quinidine, dextromethorphan or opiate drugs (codeine, etc.)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PBA Episode Rate Ratio (Post/Pre), Regression Adjusted","description":"Episodes were counted each day and recorded in a daily diary. The outcome measure is the ratio of the episode rate over the 84-day treatment period to the rate during the baseline period, adjusted for study site, and underlying disease using longitudinal negative binomial regression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.247","spread":"3.447"},{"groupId":"OG001","value":"0.237","spread":"6.048"},{"groupId":"OG002","value":"0.465","spread":"6.642"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in CNS-LS Total Score by Visit","description":"Center for Neurologic Studies-Lability Scale (CNS-LS) is an instrument for the measurement of PBA that has been validated for the use in patients with ALS and MS. It is a 7-item self-report questionnaire that measures the frequency and severity of PBA episodes, including assessments of labile laughter and labile tearfulness,and provides a score for total PBA (total score can range from 7-35). The following 5-point scoring was used: 1=Applies never, 2=Applies rarely, 3=Applies occasionally, 4=Applies frequently, 5=Applies most of the time. A score of 13 or higher may suggest PBA, and the higher the score the more severe the episodes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.77","spread":"5.239"},{"groupId":"OG001","value":"-6.27","spread":"5.552"},{"groupId":"OG002","value":"-4.58","spread":"4.982"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.03","spread":"5.591"},{"groupId":"OG001","value":"-7.62","spread":"5.421"},{"groupId":"OG002","value":"-5.70","spread":"5.034"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.59","spread":"5.745"},{"groupId":"OG001","value":"-8.89","spread":"5.501"},{"groupId":"OG002","value":"-5.66","spread":"5.038"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.17","spread":"6.104"},{"groupId":"OG001","value":"-8.24","spread":"6.126"},{"groupId":"OG002","value":"-5.72","spread":"5.280"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (EE Population)","description":"The NPI is a retrospective (to 1 month) caregiver-informant interview assessing frequency and severity of 12 neuropsychiatric symptom domains. The NPI score is based on the sum of the severity ratings (0=absent, 1=mild, 3=severe). The 12 symptom domains include delusions, hallucinations, agitation/aggression, dysphoria/depression, anxiety, euphoria/elation, apathy/indifference, disinhibition, irritability/lability, aberrant motor behaviors, nighttime behavioral disturbances, and appetite/eating abnormalities. The NPI severity score is based on severity ratings (0=absent, 1=mild to 3=severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"4.102"},{"groupId":"OG001","value":"-3.09","spread":"6.241"},{"groupId":"OG002","value":"-1.25","spread":"4.860"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.80","spread":"3.109"},{"groupId":"OG001","value":"-1.81","spread":"4.206"},{"groupId":"OG002","value":"-0.91","spread":"4.026"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Day 84 in Neuropsychiatric Inventory (NPI-Q) Frequency and Severity Score (ITT Population)","description":"The NPI is a retrospective (to 1 month) caregiver-informant interview assessing frequency and severity of 12 neuropsychiatric symptom domains. The NPI score is based on the sum of the severity ratings (0=absent, 1=mild, 3=severe). The 12 symptom domains include delusions, hallucinations, agitation/aggression, dysphoria/depression, anxiety, euphoria/elation, apathy/indifference, disinhibition, irritability/lability, aberrant motor behaviors, nighttime behavioral disturbances, and appetite/eating abnormalities. The NPI severity score is based on severity ratings (0=absent, 1=mild to 3=severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.62","spread":"4.110"},{"groupId":"OG001","value":"-2.56","spread":"6.205"},{"groupId":"OG002","value":"-1.33","spread":"4.837"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"3.102"},{"groupId":"OG001","value":"-1.59","spread":"4.128"},{"groupId":"OG002","value":"-0.98","spread":"4.008"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline at Day 84 in SF-36 (Short-Form) Health Survey Medical Outcome Score by Category","description":"The SF-36 is designed to examine a person's perceived health status. The SF-36 includes one multi-item scale measuring eight health concepts: vitality, physical functioning, bodily pain, general health perceptions, physical role-, emotional role-, social role functioning, and mental health. Answers to each question are scored and summed to produce raw scale scores for each health concept which are then transformed to a 0 - 100 scale, a high score defining a more favorable health state. An aggregate summary measure is calculated by averaging the scores from the eight health concepts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"17.336"},{"groupId":"OG001","value":"-5.30","spread":"15.652"},{"groupId":"OG002","value":"-4.05","spread":"16.381"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.47","spread":"36.747"},{"groupId":"OG001","value":"-4.26","spread":"39.764"},{"groupId":"OG002","value":"-1.75","spread":"40.084"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.09","spread":"20.861"},{"groupId":"OG001","value":"5.84","spread":"20.437"},{"groupId":"OG002","value":"-1.13","spread":"21.782"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.47","spread":"17.273"},{"groupId":"OG001","value":"-2.95","spread":"16.266"},{"groupId":"OG002","value":"-1.28","spread":"15.824"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":"17.336"},{"groupId":"OG001","value":"-5.30","spread":"15.652"},{"groupId":"OG002","value":"-4.05","spread":"16.381"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.34","spread":"25.105"},{"groupId":"OG001","value":"1.42","spread":"28.577"},{"groupId":"OG002","value":"-3.09","spread":"28.908"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.55","spread":"47.711"},{"groupId":"OG001","value":"-1.81","spread":"45.924"},{"groupId":"OG002","value":"2.36","spread":"45.984"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.53","spread":"17.067"},{"groupId":"OG001","value":"3.09","spread":"16.877"},{"groupId":"OG002","value":"-0.28","spread":"13.720"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline at Day 84 in Beck Depression Inventory (BDI-II) Total Score","description":"The BDI-II is a 21-item self report instrument intended to assess the existence and severity of symptoms of depression, summed to give a single score. The BDI-II uses a 4-point for each item ranging from 0 to 3. A total score of 0-13 is considered minimal range, 14 to 19 is mild, 20 to 28 is moderate, and 29 to 63 is severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.59","spread":"5.294"},{"groupId":"OG001","value":"-1.03","spread":"5.183"},{"groupId":"OG002","value":"-0.02","spread":"6.320"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Day 84 in Pain Rating Scale (PRS) of MS Subjects","description":"Subjects with MS were instructed to also record daily the pain they experienced using the PRS. After evaluating the subject's ability to comply with these requirements, the investigator determined if a caregiver should complete the study diary and assessments. Subjects rated their pain over the past 12 hours on a scale of 0 to 10 (0=none, 10=worst pain ever experienced).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"2.39"},{"groupId":"OG001","value":"-0.7","spread":"1.84"},{"groupId":"OG002","value":"-0.4","spread":"2.61"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":110},"commonTop":["FALL","HEADACHE","FATIGUE","DIZZINESS","NAUSEA"]}}}